J. Goldman & Co’s ChemoCentryx, Inc. CCXI Stock Holding History

J. Goldman & Co’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-45,086	Closed	-$604K	–	523
2021 Q2	$604K	Buy	+45,086	New	+$1.11M	0.02%	314
2019 Q1	–	Sell	-45,500	Closed	-$496K	–	352
2018 Q4	$496K	Buy	45,500 +13,000	+40%	+$137K	0.04%	203
2018 Q3	$411K	Hold	32,500	–	–	0.03%	229
2018 Q2	$428K	Sell	32,500 -6,500	-17%	-$77.7K	0.02%	294
2018 Q1	$530K	Buy	+39,000	New	+$402K	0.02%	281

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

J. Goldman & Co's CCXI Position: Q3 2021 in Review

J. Goldman & Co sold out of ChemoCentryx, Inc. (CCXI) in Q3 2021, closing a stake of 45,086 shares — an estimated $604K sold.

J. Goldman & Co first reported a position in CCXI in Q1 2018 and held it in 5 quarters. The position peaked at $604K in Q2 2021. 140 funds tracked by Wall St. Rank hold CCXI as of Q3 2021.

J. Goldman & Co reported no remaining ChemoCentryx, Inc. position as of Q3 2021 after selling out during the quarter.
J. Goldman & Co sold 45,086 ChemoCentryx, Inc. shares in Q3 2021, an estimated $604K.
J. Goldman & Co first reported a position in ChemoCentryx, Inc. in Q1 2018 and held it in 5 quarters.
J. Goldman & Co's ChemoCentryx, Inc. position peaked at $604K in Q2 2021.
140 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2021.

Based on J. Goldman & Co's 13F filing for Q3 2021, filed 15 Nov 2021.